No connection

Search Results

HYPR vs JYNT

HYPR
Hyperfine, Inc.
NEUTRAL
Price
$1.21
Market Cap
$119.2M
Sector
Healthcare
AI Confidence
85%
JYNT
The Joint Corp.
BEARISH
Price
$8.73
Market Cap
$125.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
HYPR
--
JYNT
--
Forward P/E
HYPR
-3.67
JYNT
38.8
P/B Ratio
HYPR
2.87
JYNT
8.2
P/S Ratio
HYPR
8.79
JYNT
2.28
EV/EBITDA
HYPR
-2.33
JYNT
137.61

Profitability

Gross Margin
HYPR
49.79%
JYNT
79.55%
Operating Margin
HYPR
-144.87%
JYNT
4.25%
Profit Margin
HYPR
-262.29%
JYNT
5.3%
ROE
HYPR
-79.01%
JYNT
-1.5%
ROA
HYPR
-40.61%
JYNT
-0.78%

Growth

Revenue Growth
HYPR
128.0%
JYNT
3.1%
Earnings Growth
HYPR
--
JYNT
6276.7%

Financial Health

Debt/Equity
HYPR
0.01
JYNT
0.13
Current Ratio
HYPR
4.34
JYNT
1.59
Quick Ratio
HYPR
3.56
JYNT
0.81

Dividends

Dividend Yield
HYPR
--
JYNT
--
Payout Ratio
HYPR
0.0%
JYNT
0.0%

AI Verdict

HYPR NEUTRAL

HYPR presents a high-risk, high-reward profile characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation benchmarks due to negative earnings. The company is experiencing explosive revenue growth (128% YoY) and maintains a strong liquidity position with a Current Ratio of 4.34 and negligible debt. However, these strengths are offset by severe profit margins (-262.29%) and a bearish insider sentiment. The stock is currently a speculative growth play where the market is pricing in future scalability rather than current fundamentals.

Strengths
Explosive revenue growth of 128% YoY
Strong liquidity with a Current Ratio of 4.34
Very low leverage (Debt/Equity of 0.01)
Risks
Severe negative profit margins (-262.29%)
Bearish insider activity with consistent selling by C-suite executives
High valuation relative to sales (P/S of 8.79) for a non-profitable firm
JYNT BEARISH

The Joint Corp. (JYNT) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. Despite a low debt-to-equity ratio, the company suffers from negative ROE (-1.50%) and a staggering 5-year price decline of 83.5%. Valuation is prohibitively high with a Price/Book ratio of 8.20 and a Forward P/E of 38.80, which is not supported by a stagnant revenue growth rate of 3.10%. The massive reported earnings growth is likely a mathematical anomaly resulting from a low base effect rather than sustainable organic growth.

Strengths
Very low Debt/Equity ratio (0.13)
Healthy Current Ratio (1.59)
Strong Gross Margins (79.55%)
Risks
Critical Piotroski F-Score (2/9) signaling fundamental decay
Severe long-term value destruction (-83.5% 5Y return)
Extreme overvaluation relative to book value (P/B 8.20)

Compare Another Pair

HYPR vs JYNT: Head-to-Head Comparison

This page compares Hyperfine, Inc. (HYPR) and The Joint Corp. (JYNT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile